Biomarin Pharmaceutical (BMRN) EBT Margin (2009 - 2026)
Biomarin Pharmaceutical (BMRN) posted EBT Margin of 18.43% for Q1 2026, up 693.57% on a QoQ basis from 3.1% in Q4 2025, and down 1352.0% year-over-year from 1.47% in Q1 2025.
Biomarin Pharmaceutical (BMRN) EBT Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical's EBT Margin history runs 18 years deep, the most recent figure standing at 18.43% for Q1 2026.
- Quarterly EBT Margin fell 1352.0% year-over-year to 18.43% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.89% (down 1096.0% YoY) and the FY2025 annual result came in at 14.98%, down 401.0% from the prior year.
- EBT Margin was 18.43% for Q1 2026 at Biomarin Pharmaceutical, up from 3.1% in the prior quarter.
- Across five years, EBT Margin topped out at 36.09% in Q2 2025 and bottomed at 3.39% in Q3 2025.
- A 5-year average of 12.7% and a median of 11.9% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin soared 2106 bps — and 2025, when it plunged 2580 bps.
- Biomarin Pharmaceutical's EBT Margin stood at 3.27% in 2022, then jumped by 192 bps to 2.99% in 2023, then jumped by 659 bps to 22.7% in 2024, then plunged by 114 bps to 3.1% in 2025, then jumped by 694 bps to 18.43% in 2026.
- Business Quant data shows BMRN's EBT Margin at 18.43% in Q1 2026, 3.1% in Q4 2025, and 3.39% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn | 18.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.43% |
| Dec 31, 2025 | -3.10% |
| Sep 30, 2025 | -3.39% |
| Jun 30, 2025 | 36.09% |
| Mar 31, 2025 | 31.95% |
| Dec 31, 2024 | 22.70% |
| Sep 30, 2024 | 18.03% |
| Jun 30, 2024 | 18.56% |
| Mar 31, 2024 | 16.27% |
| Dec 31, 2023 | 2.99% |
| Sep 30, 2023 | 7.17% |
| Jun 30, 2023 | 11.90% |
| Mar 31, 2023 | 9.52% |
| Dec 31, 2022 | -3.27% |
| Sep 30, 2022 | -0.38% |
| Jun 30, 2022 | 6.53% |
| Mar 31, 2022 | 25.84% |
| Dec 31, 2021 | -14.80% |
| Sep 30, 2021 | -11.29% |
| Jun 30, 2021 | 2.82% |